# Systemic Treatment for Hepatocellular Carcinoma Recurrence After Liver Transplantation

## TL;DR

This paper reviews treatment options for liver cancer recurrence after liver transplants, focusing on systemic therapies and immunosuppression strategies.

## Contribution

The paper provides a synthesis of current evidence and highlights the need for prospective studies on systemic therapies for post-transplant liver cancer recurrence.

## Key findings

- Post-transplant liver cancer recurrence occurs in 8–20% of cases and has a poor prognosis.
- Systemic therapies like tyrosine kinase inhibitors and immunotherapy are mainstays for advanced recurrence.
- Immunosuppression strategies, such as calcineurin inhibitor minimization, are critical for managing tumor progression.

## Abstract

Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality worldwide. Liver transplantation (LT) represents the only curative treatment for both HCC and the underlying liver disease; however, post-transplant recurrence occurs in 8–20% of recipients and is associated with a poor prognosis. The management of recurrent HCC after LT is particularly challenging due to the need for lifelong immunosuppression, which may promote tumor progression and limit therapeutic options. In patients with advanced or multifocal recurrence, systemic therapy is the mainstay of treatment. Optimization of immunosuppressive regimens, particularly calcineurin inhibitor minimization and selective use of mTOR inhibitors, is critical.

Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality worldwide, and liver transplantation (LT) remains the only curative treatment addressing both tumor burden and underlying liver disease. Despite an adequate candidate selection, HCC recurrence after LT occurs in 8–20% of cases and is associated with a poor prognosis, particularly in patients who experience an early relapse. The management of HCC recurrence remains particularly challenging due to the lifelong immunosuppression required after LT, which may promote tumor progression and restrict therapeutic options. This review synthesizes the current evidence on systemic therapies for recurrent HCC after LT, focusing on tyrosine kinase inhibitors (TKIs), immunotherapy, and the current available immunosuppression strategies. Unfortunately, in this setting, robust prospective studies are lacking, and clinical decision-making remains based on retrospective data and expert consensus. Future research should prioritize the prospective evaluation of systemic regimens, integration of immunosuppression modulation, and careful exploration of immunotherapy or new target therapies in this special population.